AIMS: To investigate the expression of the human ccn3 (hccn3; nov) proto-oncogene, a member of the CCN family of proteins, in prostate epithelial cells and prostate tissue samples. METHODS: Normal adult prostate luminal epithelial cells immortalised by SV40 large T (PNT1A and PNT1B), metastatic tumours (LNCaP, DU-145, and PC-3), and prostate tissue samples from patients with benign prostatic hyperplasia (BPH) and prostatic adenocarcinoma were used. hccn3 (nov) mRNA was measured by the reverse transcription polymerase chain reaction (RT-PCR) and hCCN3 (NOV) protein expression was determined by immunochemistry. RESULTS: hccn3 (nov) RNA values were higher in PC-3 cells than in the other prostate cell lines. The immortalised normal cell lines either did not express hccn3 (nov) RNA (PNT1B) or expressed very low amounts (PNT1A). BPH samples expressed variable amounts of hccn3 (nov) RNA. With the use of immunocytochemistry, all cell lines except PNT1A and PNT1B were shown to contain hCCN3 (NOV) protein. hCCN3 (NOV) was localised mainly in the epithelial compartment of BPH and adenocarcinoma samples, and there was evidence of luminal secretion. CONCLUSION: The overexpression of hccn3 (nov) RNA in cancer cell lines compared with other cell lines and its epithelial localisation in human prostate samples are consistent with a role for hCCN3 (NOV) in prostatic tumorigenesis.
AIMS: To investigate the expression of the humanccn3 (hccn3; nov) proto-oncogene, a member of the CCN family of proteins, in prostate epithelial cells and prostate tissue samples. METHODS: Normal adult prostate luminal epithelial cells immortalised by SV40 large T (PNT1A and PNT1B), metastatic tumours (LNCaP, DU-145, and PC-3), and prostate tissue samples from patients with benign prostatic hyperplasia (BPH) and prostatic adenocarcinoma were used. hccn3 (nov) mRNA was measured by the reverse transcription polymerase chain reaction (RT-PCR) and hCCN3 (NOV) protein expression was determined by immunochemistry. RESULTS:hccn3 (nov) RNA values were higher in PC-3 cells than in the other prostate cell lines. The immortalised normal cell lines either did not express hccn3 (nov) RNA (PNT1B) or expressed very low amounts (PNT1A). BPH samples expressed variable amounts of hccn3 (nov) RNA. With the use of immunocytochemistry, all cell lines except PNT1A and PNT1B were shown to contain hCCN3 (NOV) protein. hCCN3 (NOV) was localised mainly in the epithelial compartment of BPH and adenocarcinoma samples, and there was evidence of luminal secretion. CONCLUSION: The overexpression of hccn3 (nov) RNA in cancer cell lines compared with other cell lines and its epithelial localisation in human prostate samples are consistent with a role for hCCN3 (NOV) in prostatic tumorigenesis.
Authors: R J Matusik; W H Fleming; A Hamel; T G Westenbrink; B Hrabarchuk; R MacDonald; E Ramsey; J G Gartner; N M Pettigrew; B Johnston Journal: Prog Clin Biol Res Date: 1987
Authors: O Cussenot; P Berthon; R Berger; I Mowszowicz; A Faille; F Hojman; P Teillac; A Le Duc; F Calvo Journal: J Urol Date: 1991-09 Impact factor: 7.450
Authors: Véronique Ouellet; Kerstin Tiedemann; Anna Mourskaia; Jenna E Fong; Danh Tran-Thanh; Eitan Amir; Mark Clemons; Bernard Perbal; Svetlana V Komarova; Peter M Siegel Journal: Am J Pathol Date: 2011-05 Impact factor: 4.307
Authors: Daniel Kagedan; Irene Lecker; Ihor Batruch; Christopher Smith; Ilia Kaploun; Kirk Lo; Ethan Grober; Eleftherios P Diamandis; Keith A Jarvi Journal: Clin Proteomics Date: 2012-02-06 Impact factor: 3.988
Authors: Guo-Wei Zuo; Christopher D Kohls; Bai-Cheng He; Liang Chen; Wenli Zhang; Qiong Shi; Bing-Qiang Zhang; Quan Kang; Jinyong Luo; Xiaoji Luo; Eric R Wagner; Stephanie H Kim; Farbod Restegar; Rex C Haydon; Zhong-Liang Deng; Hue H Luu; Tong-Chuan He; Qing Luo Journal: Histol Histopathol Date: 2010-06 Impact factor: 2.303
Authors: Carolyn J M Best; John W Gillespie; Yajun Yi; Gadisetti V R Chandramouli; Mark A Perlmutter; Yvonne Gathright; Heidi S Erickson; Lauren Georgevich; Michael A Tangrea; Paul H Duray; Sergio González; Alfredo Velasco; W Marston Linehan; Robert J Matusik; Douglas K Price; William D Figg; Michael R Emmert-Buck; Rodrigo F Chuaqui Journal: Clin Cancer Res Date: 2005-10-01 Impact factor: 12.531
Authors: Lynn McCallum; Wanhua Lu; Susan Price; Noureddine Lazar; Bernard Perbal; Alexandra E Irvine Journal: J Cell Commun Signal Date: 2009-07-22 Impact factor: 5.782